OTCQX:MRVFF - Post by User
Post by
PDMitchellon Mar 18, 2013 9:28am
394 Views
Post# 21144648
Nuvo Research provides additional information rega
Nuvo Research provides additional information rega Nuvo Research provides additional information regarding Pennsaid 2%
MISSISSAUGA, ON, March 18, 2013 /CNW/ - Nuvo Research Inc. (Nuvo) (TSX:NRI) announced today that a Question and Answer document has been posted on its website to provide additional information to Nuvo shareholders regarding the regulatory status of Pennsaid 2% in the United States. Follow this link to access the document - Pennsaid 2% Q&A.
Pennsaid 2%
Pennsaid 2% is the follow-on product to original Pennsaid, a topical non-steroidal anti-inflammatory drug (NSAID). Pennsaid 2%, which is not yet approved by the FDA, contains 2% diclofenac sodium compared to 1.5% for original Pennsaid. It is more viscous than original Pennsaid, is supplied in a metered dose pump bottle and is designed to be applied twice each day compared to four times a day for original PENNSAID.